Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. Juli 2018 07:30 ET | Quelle: Moleculin Biotech, Inc.

Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia

HOUSTON, July 18, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
11. Juli 2018 07:30 ET | Quelle: Moleculin Biotech, Inc.

Moleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover

HOUSTON, July 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
26. Juni 2018 07:30 ET | Quelle: Moleculin Biotech, Inc.

Moleculin Selected for the Russell Microcap Index

HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
21. Juni 2018 07:30 ET | Quelle: Moleculin Biotech, Inc.

Moleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market

HOUSTON, June 21, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer...
20. Juni 2018 07:30 ET | Quelle: Moleculin Biotech, Inc.

Moleculin Receives Approval for Leukemia Clinical Trial

HOUSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
12. Juni 2018 07:30 ET | Quelle: Moleculin Biotech, Inc.

Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors

HOUSTON, June 12, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
06. Juni 2018 09:09 ET | Quelle: Moleculin Biotech, Inc.

Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa

HOUSTON, June 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
24. Mai 2018 08:30 ET | Quelle: Moleculin Biotech, Inc.

Moleculin Invited to Present to International BioForum 2018 Conference

HOUSTON, May 24, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
16. Mai 2018 08:30 ET | Quelle: Moleculin Biotech, Inc.

Moleculin to Begin Clinical Trials at UMC Southwest Cancer Center

HOUSTON, May 16, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
15. Mai 2018 08:30 ET | Quelle: Moleculin Biotech, Inc.

Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2018

HOUSTON, May 15, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...

Vorherige Seite

Nächste Seite